Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Operating activities
Net income (loss)	$ 2,418		$ (69,180)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	2,918		3,058
Non-cash operating lease cost	759		842
Non-cash interest expense and amortization of debt issuance costs	2,098		4,386
Payment on Scilex Notes attributed to accreted interest related to the debt discount	(4,548)
Acquired in-process research and development	7,512
Stock-based compensation	23,660		3,682
Loss on debt extinguishment	6,111		23,645
Gain on derivative liabilities	(2,200)		(4,920)
Gain on marketable investment	(94,431)
Loss on equity method investments	419		556
Deferred tax provision	(219)		(150)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(803)		4,432
Accrued payroll	(4,573)		(407)
Prepaid expenses, deposits and other assets	980		185
Accounts payable	(76)		728
Accrued expenses and other liabilities	11,066		(4,488)
Deferred revenue	376		(169)
Other	476		(750)
Net cash used for operating activities	(48,057)		(38,550)
Investing activities
Purchases of property and equipment	(1,994)		(21)
Other acquisitions and investments	(12)
Net cash used for investing activities	(2,006)		(21)
Financing activities
Proceeds from short-term debt, net of issuance costs	11,769		725
Proceeds from exercise of stock options and warrants	10,597		13,634
Repayments of debt and other obligations	(29,218)		(59,533)
Net cash provided by financing activities	35,357		24,722
Net change in cash, cash equivalents and restricted cash	(14,706)		(13,849)
Net effect of exchange rate changes on cash	(80)		27
Cash, cash equivalents and restricted cash at beginning of period	56,464		80,769
Cash, cash equivalents and restricted cash at end of period	41,678	$ 56,464	66,947
Cash paid during the period for:
Interest	83		1,569
Supplemental disclosures of non-cash investing and financing activities:
Changes to noncontrolling interests from increased ownership in Scilex Holding	23,963
Other acquisitions, license agreements and investments paid in equity	7,500
Property and equipment costs incurred but not paid	1,031		628
Non-cash additions related to leasehold improvements	2,279
Reconciliation of cash, cash equivalents and restricted cash within the Company’s consolidated balance sheets:
Cash and cash equivalents	41,678	$ 56,464	21,897
Restricted cash			45,050
Cash, cash equivalents, and restricted cash	41,678		66,947
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 42,209		$ 69,896